1.51
price down icon4.43%   -0.07
after-market Handel nachbörslich: 1.48 -0.03 -1.99%
loading
Schlusskurs vom Vortag:
$1.58
Offen:
$1.5
24-Stunden-Volumen:
1.26M
Relative Volume:
0.40
Marktkapitalisierung:
$85.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.44M
KGV:
-0.8032
EPS:
-1.88
Netto-Cashflow:
$-66.75M
1W Leistung:
-9.58%
1M Leistung:
-20.94%
6M Leistung:
-58.74%
1J Leistung:
-69.80%
1-Tages-Spanne:
Value
$1.43
$1.53
1-Wochen-Bereich:
Value
$1.43
$1.65
52-Wochen-Spanne:
Value
$1.43
$7.66

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name
Firmenname
Black Diamond Therapeutics Inc
Name
Telefon
617-417-5868
Name
Adresse
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Name
Mitarbeiter
54
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
BDTX's Discussions on Twitter

Vergleichen Sie BDTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BDTX
Black Diamond Therapeutics Inc
1.51 85.56M 0 -82.44M -66.75M -1.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-31 Eingeleitet Raymond James Outperform
2023-07-14 Eingeleitet Piper Sandler Overweight
2023-06-30 Hochstufung Stifel Hold → Buy
2023-06-28 Hochstufung H.C. Wainwright Neutral → Buy
2023-06-27 Hochstufung Wedbush Neutral → Outperform
2022-03-29 Herabstufung Wedbush Outperform → Neutral
2022-03-22 Herabstufung H.C. Wainwright Buy → Neutral
2021-09-30 Eingeleitet Stifel Hold
2021-01-07 Eingeleitet Wedbush Outperform
2020-11-24 Eingeleitet Berenberg Buy
2020-05-04 Eingeleitet H.C. Wainwright Buy
2020-02-24 Eingeleitet Canaccord Genuity Buy
2020-02-24 Eingeleitet Cowen Outperform
2020-02-24 Eingeleitet JP Morgan Overweight
2020-02-24 Eingeleitet Jefferies Buy
Alle ansehen

Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten

pulisher
Mar 31, 2025

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Mar 31, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle

Mar 27, 2025
pulisher
Mar 26, 2025

BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 25, 2025

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha

Mar 25, 2025
pulisher
Mar 24, 2025

What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Small Cap Stocks To Follow TodayMarch 19th - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus

Mar 22, 2025
pulisher
Mar 21, 2025

Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Growth Stocks To Add to Your Watchlist – March 19th - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat

Mar 20, 2025
pulisher
Mar 19, 2025

Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com

Mar 19, 2025
pulisher
Mar 19, 2025

Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts

Mar 19, 2025
pulisher
Mar 19, 2025

This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond Therapeutics surges on licensing deal - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha

Mar 19, 2025
pulisher
Mar 19, 2025

Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Servier and Black Diamond enter oncology licensing deal - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond rises on licensing deal for tumor treatment - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Black Diamond stock soars on licensing deal By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

HC Wainwright Issues Positive Forecast for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Black Diamond Therapeutics Reports 2024 Financial Results - MSN

Mar 18, 2025
pulisher
Mar 13, 2025

Black Diamond Therapeutics: In Decline, But Why? (NASDAQ:BDTX) - Seeking Alpha

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Has $120,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

BDTX stock touches 52-week low at $1.76 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

BDTX stock touches 52-week low at $1.76 amid market challenges By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Black Diamond Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Brokers Issue Forecasts for BDTX Q1 Earnings - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Stifel Nicolaus Lowers Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $15.00 - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Wedbush Reiterates Outperform Rating for Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World

Mar 09, 2025

Finanzdaten der Black Diamond Therapeutics Inc-Aktie (BDTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):